✦ LIBER ✦

Levonorgestrel intrauterine system for endometrial hyperplasia

Book ID: 120845856
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200716010-00024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Levonorgestrel-releasing intrauterine sy

Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study

✍ Gianfranco Scarselli; Gianni Bargelli; Gian Luigi Taddei; Mauro Marchionni; Elen 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Treatment of nonatypical and atypical en

Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system

✍ D. Wildemeersch; M. Dhont 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Endometrial resection following levonorg

Endometrial resection following levonorgestrel intrauterine system treatment for menorrhagia

✍ Pentti K. Heinonen; Riikka Helin 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 94 KB

Levonorgestrel-Releasing Intrauterine De

Levonorgestrel-Releasing Intrauterine Device Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

✍ El Behery, M. M.; Saleh, H. S.; Ibrahiem, M. A.; Kamal, E. M.; Kassem, G. A.; Mo 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 203 KB

Endometrial effects of intrauterine levo

Endometrial effects of intrauterine levonorgestrel

✍ Anja Guttinger; Hilary O.D. Critchley 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Levonorgestrel-impregnated intrauterine

Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial

✍ Ørbo, A; Vereide, AB; Arnes, M; Pettersen, I; Straume, B 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

## Objective The purpose of this study was to investigate if the levonorgestrel-impregnated intrauterine device (LNG-IUS, Mirena®) is safe and effective as therapy for low-risk and medium-risk endometrial hyperplasia compared with oral medroxyprogesterone (MPA). ## Design A multicentre randomised